The following tables provide amounts by year indicated and by line item included in the Company's accompanying consolidated statements of operations and comprehensive loss attributable to transactions arising from its significant collaborative arrangements, as defined in the FASB's ASC Topic 808, Collaborative Arrangements, and all other arrangements. The amounts in operating expenses generally represent external expenditures, including amortization of an intangible asset, and exclude salaries and benefits, share-based compensation, facilities, depreciation and laboratory supplies, as the majority of such costs are not directly charged to programs. The dollar amounts in the tables below are in thousands.



	For the Year Ended December 31, 2017
	2003 Sandoz Collaboration Agreement		2006 Sandoz Collaboration Agreement		Mylan Collaboration Agreement			CSL License Agreement			Total Collaborations
Collaboration revenues:
Product revenue	$	313	$	66,490	$	—		$	—		$	66,803
Research and development revenue:
Commercial milestone (2)	—		10,000		—			—			10,000
Recognition of upfront payments	—		—		5,015			50,000			55,015
Research and development services and external costs	2,856		2,142		—			2,066			7,064
Total research and development revenue	$	2,856	$	12,142	$	5,015		$	52,066		$	72,079
Total collaboration revenues	$	3,169	$	78,632	$	5,015		$	52,066		$	138,882
Operating expenses:
Research and development expense	$	1,958	$	1,766	$	62,049		$	8,179		$	73,952
General and administrative expense	15,426		494		3,617			124			19,661
Less: net amount recovered from collaborators	—		—		(25,835		)	(3,320		)	(29,155		)
Total operating expenses	$	17,384	$	2,260	$	39,831		$	4,983		$	64,458



	For the Year Ended December 31, 2016
	2003 Sandoz Collaboration Agreement		2006 Sandoz Collaboration Agreement		Mylan Collaboration Agreement			Baxalta Collaboration Agreement (1)		Total Collaborations
Collaboration revenues:
Product revenue	$	—	$	74,648	$	—		$	—	$	74,648
Research and development revenue:
Recognition of upfront payments and license fee	—		—		6,368			21,983		28,351
Research and development services and external costs	345		2,545		—			3,730		6,620
Total research and development revenue	$	345	$	2,545	$	6,368		$	25,713	$	34,971
Total collaboration revenues	$	345	$	77,193	$	6,368		$	25,713	$	109,619
Operating expenses:
Research and development expense	$	692	$	1,911	$	55,147		$	1,196	$	58,946
General and administrative expense	7		470		3,009			187		3,673
Less: net amount recovered from collaborator	—		—		(27,770		)	—		(27,770		)
Total operating expenses	$	699	$	2,381	$	30,386		$	1,383	$	34,849



	For the Year Ended December 31, 2015
	2003 Sandoz Collaboration Agreement		2006 Sandoz Collaboration Agreement		Baxalta Collaboration Agreement (1)		Total Collaborations
Collaboration revenues:
Product revenue	$	5,063	$	43,440	$	—	$	48,503
Research and development revenue:
Milestones	—		20,000		—		20,000
Recognition of upfront payment and license fee	—		—		9,014		9,014
Research and development services and external costs	789		2,861		8,483		12,133
Total research and development revenue	$	789	$	22,861	$	17,497	$	41,147
Total collaboration revenues	$	5,852	$	66,301	$	17,497	$	89,650
Operating expenses:
Research and development expense	$	324	$	856	$	1,851	$	3,031
General and administrative expense	344		206		963		1,513
Total operating expenses	$	668	$	1,062	$	2,814	$	4,544

_______________________________________


(1)	The Baxalta Collaboration Agreement was terminated effective December 31, 2016.


(2)	On July 1, 2017, the Company earned a $10.0 million commercial milestone for which Sandoz was entitled to reduce contractual net profit in a corresponding amount under the terms of the 2006 Sandoz Collaboration Agreement.